Gary J. Nabel - 23 Jun 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Director
Issuer ticker: CADL
Reported as of: 23 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jun 2026, 16:28:29 UTC
Prior SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-In-Fact for Gary J. Nabel

Key filing fact

Gary J. Nabel filed Form 4 for Candel Therapeutics, Inc. (CADL) on 24 Jun 2026.

Key facts

This page summarizes Gary J. Nabel's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jun 2026, 16:28.

Change

Previous filing in this sequence was filed on 10 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867450 Primary reporting owner

Nabel Gary J.

Relationship: Director
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-In-Fact for Gary J. Nabel
Signature date: 24 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +32,000
Change %
Price: $0.000000^*
Shares after: 32,000
Date: 23 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,000
Exercise price: $9.08
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.